Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Polynucleotides vs Hyaluronic Acid Fillers
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The key decision is whether the symptom has been properly assessed first.
Direct answer
Polynucleotides and hyaluronic acid fillers or skin boosters work differently. Hyaluronic acid mainly attracts and holds water; cross-linked fillers can add volume. Polynucleotides are biostimulatory DNA fragments intended to support gradual tissue repair, fibroblast activity and extracellular-matrix quality. In intimate health, the choice should depend on the symptom, tissue findings, product type and safety profile, not on a generic rejuvenation promise.
The safest plan starts by clarifying the symptom, checking red flags, explaining alternatives and agreeing realistic expectations before any procedure is booked.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Polynucleotides (PNs)
Bioactive molecules derived from highly purified fish DNA (salmon or trout) that act as biostimulators to upregulate collagen and.
Hyaluronic Acid (HA) Boosters
Non-crosslinked HA formulations primarily intended to attract and bind water within the superficial mucosa for enhanced hydration .
Combination Therapies (e.g., NewGyn)
specialised products that combine PNs, HA, and mannitol (an antioxidant that protects HA from rapid degradation) to maximize both.
Standard Fillers
Crosslinked HA gels used strictly for aesthetic contouring and volume replacement in the labia .
Important safety note
Common Side Effects: Transient localised swelling, pinpoint bruising, spotting, and mild tenderness at the injection sites, which typically resolve within 24 to 72 hours .
Allergy
Technique
Timeline
Aftercare
Detailed answer
How polynucleotides fit into intimate care
Polynucleotides are best explained as biostimulatory DNA fragments rather than fillers. The clinical question is whether they match the diagnosis, tissue findings and safety profile.
Not a standard filler
The aim is gradual tissue-quality support through repair signalling, hydration and extracellular-matrix activity, not instant volume or a promised sexual-function outcome.
Evidence
Symptoms
Alternatives
What it means
Foundational Care: Injectables are considered an adjunct therapy. The clinical gold standard and first-line treatment for GSM and vaginal atrophy remains non-hormonal moisturisers/lubricants and low-dose local vaginal oestrogen .
Why it happens
Medical Organization Stance: The American College of Obstetricians and gynaecologists (ACOG) cautions that many cosmetic vaginal procedures are "not medically indicated" and highlights a lack of robust, long-term data supporting.
Evidence limits
Regulatory Oversight: In the UK, dermal fillers and skin boosters are classified as Class III medical devices. Ensuring that a product is properly UKCA/CE-marked for intended vulvovaginal use is essential.
Treatment fit
Pre-Procedure: Patients are advised to stop Aspirin, NSAIDs, and supplements that increase bleeding risk (e.g., Vitamin E, fish oil) up to 1 week prior . A topical anaesthetic cream is.
What this means in practice
Medication and supplement planning should be individualised, especially if bruising or bleeding risk is higher.
Procedure Duration: Treatments are performed in an outpatient clinic and typically take 10 to 30 minutes .
Patient safety
Why diagnosis comes first
Dryness, soreness, tearing or painful sex may reflect GSM, infection, dermatoses, pelvic-floor guarding or medication effects, so the treatment choice depends on assessment.
It checks the cause
Foundational Care: Injectables are considered an adjunct therapy. The clinical gold standard and first-line treatment for GSM and vaginal atrophy remains non-hormonal moisturisers/lubricants and.
It protects safety
Common Side Effects: Transient localised swelling, pinpoint bruising, spotting, and mild tenderness at the injection sites, which typically resolve within 24 to 72 hours.
It reviews alternatives
The comparison should include alternatives such as moisturisers, local hormonal care, pelvic-floor therapy or specialist review.
It sets expectations
Procedure Duration: Treatments are performed in an outpatient clinic and typically take 10 to 30 minutes .
Non-hormonal does not mean automatic
A hormone-free treatment may still be unsuitable if there is active infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
The consultation should cover product source, allergy risk, alternatives such as moisturisers or local hormonal care, and realistic timelines for tissue response.
Considerations
What to consider
The decision should start with the symptom and tissue findings, then compare hydration, biostimulation, volume effect, safety and aftercare.
Consultation priorities
Initial Consultation: A thorough medical evaluation by a qualified practitioner to assess GSM symptoms, review medical history, confirm suitability, and manage realistic expectations .
Consent
Aftercare
Follow-up
Before treatment
Initial Consultation: A thorough medical evaluation by a qualified practitioner to assess GSM symptoms, review medical history, confirm suitability, and manage realistic expectations .
During care
Treatment Session: After local numbing, the practitioner uses fine needles (e.g., 30G) to deliver the product. Skin boosters/PNs are injected superficially (micro-wheal or linear retrograde technique) into the.
Aftercare
Follow-Up and Maintenance: Patients generally return to normal daily activities immediately. A clinical review is typically scheduled at 6 to 12 weeks to evaluate symptom improvement, with maintenance.
When to reassess
If the expected response does not occur, reassessment is safer than automatic repeat treatment.
Practical expectations
Procedure Duration: Treatments are performed in an outpatient clinic and typically take 10 to 30 minutes .
Post-Procedure Care: Patients should avoid sexual intercourse, intense physical activity, tight clothing, and hot baths/saunas for 48 to 72 hours to prevent friction and infection .
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments, usually used for gradual tissue-quality support rather than volume.
Myth: hormone-free means suitable for everyone
Reality: allergy, infection, bleeding, pregnancy, recent surgery and unexplained pain can still make treatment unsuitable.
Myth: hydration means instant repair
Reality: hydration may be noticed earlier, but collagen and tissue-quality changes are gradual and variable.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable clinical result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be more appropriate for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Do not claim intimate polynucleotides cure dryness, laxity, sexual dysfunction, pelvic symptoms, scarring or menopause-related tissue change. Explain that PN products are often fish/marine-derived and allergy history matters.
Are alternatives clear?
Ask whether a hydrating product, a biostimulatory product or no injectable treatment is the safest option for the concern.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, severe fish allergy, pregnancy, recent pelvic surgery or severe pain that has not been assessed.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips or tongue, breathing difficulty, widespread hives, faintness or collapse after exposure needs urgent medical help.
Bleeding or infection
New post-menopausal bleeding, unusual discharge, fever, pelvic pain, thrush, BV or UTI symptoms should be assessed before injectable treatment.
Infection signs
Filler-Specific Risks: Deep crosslinked fillers carry risks of granuloma or nodule formation, contour irregularities, and rare but severe arterial occlusion .
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support cautious, assessment-led patient information and help separate clinical evidence from promotional claims.
PubMed: PN/HA intradermal injections for vulvovaginal atrophy
This pilot study is directly relevant to polynucleotide and hyaluronic acid use in vulvovaginal atrophy.
Real-world study of polynucleotide-based vaginal ovules
This source supports cautious discussion of PN-based vaginal ovules, hydration and atrophy-related symptoms.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 59 imported records. Additional reviewed material included peer-reviewed clinical papers; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
